Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVA-LTE long-term mavacamten extension in adults with hypertrophic cardiomyopathy
NL-OMON59611Phase 3Completed
- Sponsor
- MyoKardia
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Started Dec 2019; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON59611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59611.